Tracers / [90Y]Y-90-ITGA6B4
[90Y]Y-90-ITGA6B4
Also written as Y-90-ITGA6B4
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- Radiolabeled anti-integrin α6β4 monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- Targets integrin α6β4 (α6β4) overexpressed on tumor cells PMID 27246980
- Clinical application
- Radioimmunotherapy of pancreatic cancer xenografts PMID 27246980
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 80 | >95% | CHX-A''-DTPA-conjugated anti-α6β4 antibody (ITGA6B4) Macrocyclics | 29204055 2017 World J Gastroenterol Human anti-α6β4 monoclonal antibody (IgG1) was labeled with beta-emitter 90Y, as previously reported[30]. — The radiochemical yield was approximately 80% |
| Manual synthesis | — | SPE | 85 to 90% | >99% | CHX-A′′-DTPA Macrocyclics | 27246980 2016 Oncotarget Human anti-α6β4 monoclonal antibody (IgG1) was labeled with 90Y, as previously reported — The radiochemical yield was approximately 85 to 90% |
Need this precursor?We can point you to suppliers for [90Y]Y-90-ITGA6B4, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 29204055: 'CHX-A''-DTPA-conjugated anti-α6β4 antibody (ITGA6B4)'.